Lilly Stays Confident In Possible COVID Drug After Setback
FILE - In this May 2020 file photo provided by Eli Lilly, a researcher tests possible COVID-19 antibodies in a laboratory in Indianapolis. On Monday, Oct. 26, 2020, U.S. government officials announced they are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it doesnt seem to help. (David Morrison/Eli Lilly via AP, File)
The drugmaker said Tuesday it remains confident that its drug may stop COVID from developing in other patients. Researchers are still studying the drug in mild to moderately ill patients, to try to prevent hospitalization and severe illness.
U.S. government officials said Monday that they put an early end to a study testing the antibody drug in hospitalized patients because it doesnt seem to be helping them.
Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated.
Lilly shares tumbled in early-morning trading Tuesday after the company also laid out disappointing third-quarter results.
Global revenue climbed 5% to $5.74 billion, and adjusted earnings totaled $1.54 per share.
Analysts expected, on average, earnings of $1.71 per share on $5.87 billion in revenue, according to FactSet.
Shares of Indianapolis-based Eli Lilly and Co. fell 4% to $136.01 before markets opened.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor